TGFB1 and Hepatic fibrosis: These findings indicate that through manipulating the miRNA expressions, we can effectively disrupt TGF-β-induced fibrogenesis, inactivate HSC, inhibit ECM remodeling, and attenuate liver fibrosis, and highlight the potential of miRNA-based therapeutic strategies for early intervention in liver disease.